For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
Research Comparison
CJC-1295 is a GHRH analog that acts on the GHRH receptor, while Ipamorelin is a selective GH secretagogue acting on GHSR-1a. They target different receptors in the same growth-hormone axis, which is why researchers frequently study them together rather than as substitutes.
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Receptor target | GHRH receptor | GH secretagogue receptor (GHSR-1a) |
| Class | GHRH analog | GH secretagogue (GHRP) |
| Signaling profile | Sustained, long-acting (DAC) | Pulsatile, short-acting |
| Off-target release | Low | Very low (cortisol/prolactin sparing) |
| Common pairing | Paired with a GHRP | Paired with a GHRH analog |
Yes — because they act on different receptors in the growth-hormone axis, they are commonly combined in research to study synergistic GH pulse amplitude and frequency. We also offer a pre-made CJC-1295 + Ipamorelin blend.
CJC-1295 is a GHRH analog providing sustained receptor activation, while Ipamorelin is a selective secretagogue producing a clean, pulsatile signal. They are complementary rather than interchangeable.